anti-Synovial Sarcoma, X Breakpoint 1 (SSX1) Antibodies

Human Synovial Sarcoma, X Breakpoint 1 (SSX1) interaction partners

1. Synovial sarcoma (SS) is considered as high-grade tumors with a poor prognosis. Novel therapies targeted at fusion oncogene (show RAB1A Antibodies), SS18 (show SS18 Antibodies)-SSX (show SSX2 Antibodies)-derived peptide vaccine, epidermal growth factor receptor (show EGFR Antibodies), and vascular endothelial growth factor (show VEGF Antibodies) are the future hope in SS.

2. Data indicate that the oncogene (show RAB1A Antibodies) SS18 (show SS18 Antibodies)-SSX1 promotes tumorigenesis by increasing the expression of SHC SH2-domain binding protein 1 (SHCBP1 (show SHCBP1 Antibodies)), which normally acts as a tumor promoting factor.

3. In patients with Colon cancer, the expression of SSX1 gene was associated with a poor prognosis.

4. Meta-analysis of human synovial sarcoma patient series identified two tumor-gentoype-phenotype correlations that were not modeled by the mice, namely a scarcity of male hosts and biphasic histologic features among SS18 (show SS18 Antibodies)-SSX2 (show SSX2 Antibodies) tumors. Re-analysis of human SS18 (show SS18 Antibodies)-SSX1 and SS18 (show SS18 Antibodies)-SSX2 (show SSX2 Antibodies) tumor transcriptomes demonstrated very few consistent differences, but highlighted increased native SSX2 (show SSX2 Antibodies) expression in SS18 (show SS18 Antibodies)-SSX1 tumors.

5. Data show that SS18 (show SS18 Antibodies)/SSX (show SSX2 Antibodies) tightly regulates the elevated expression of the key Wnt (show WNT2 Antibodies) target AXIN2 (show AXIN2 Antibodies) in primary synovial sarcoma.

6. a rare variant of the SS18 (show SS18 Antibodies)-SSX1 fusion transcript, which could not be identified by routine procedures for genetic diagnosis, was detected. In addition, 8 missense mutations of cancer-related genes were confirmed

7. SS18 (show SS18 Antibodies)-SSX (show SSX2 Antibodies)-induced Wnt (show WNT2 Antibodies)/beta-catenin (show CTNNB1 Antibodies) signaling appears to be of crucial biological importance in synovial sarcoma tumorigenesis and progression.

8. The mRNA levels of SSX1 and SSX4 (show SSX4 Antibodies) are associated with multiple myeloma clinical stage

9. These results suggest that the characteristic speckle localization pattern of SS18 (show SS18 Antibodies)-SSX (show SSX2 Antibodies) is strongly involved in the tumorigenesis through the SSX (show SSX2 Antibodies) moiety of the SS18 (show SS18 Antibodies)-SSX (show SSX2 Antibodies) fusion protein.

10. Knockdown of SS18 (show SS18 Antibodies)-SSX1 in synovial sarcoma inhibits viability and induces apoptosis.